Company intelligence / Profile preview

Silma

Elektrostal, Moscow Oblast, Russia

Ownership: Private
Development stage: Other

Overview

TNC SILMA is a pharmaceutical company primarily known for the development and manufacture of Enterosgel, an innovative organosilicon-based intestinal adsorbent. The company's flagship product, Enterosgel (polymethylsiloxane polyhydrate), is used globally for the detoxification of the body, treating conditions such as acute and chronic diarrhea, allergies, and various gastrointestinal disorders. TNC SILMA operates in both the medical and veterinary sectors, providing original products based on its proprietary organosilicon technology. The company has a significant international presence, with its products registered and sold in over 40 countries across Europe, Asia, and the CIS region.

Therapeutic areas: ImmunologyOtherGastroenterology
Modalities: Small moleculeOrganosilicon polymer
Industry: Biotech

Beyond the preview

Go deeper on Silma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Silma.

Explore the full profile